Immune cell modulators (ICM) are a novel therapeutic class with the potential to treat autoimmune and inflammatory diseases across a broad range of therapeutic areas, including rheumatology, gastroenterology, respiratory, dermatology and neurology.
Anaptys’ ICMs are engineered to have a top-down, broad impact on the most pathogenic cells driving disease by targeting specific activated immune cells in periphery and tissue.
- Poster Presentation
June, 2025 — Federation of Clinical Immunology Societies (FOCiS) Annual Meeting
Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Ren et al., 2025
- Poster Presentation
June, 2025 — Federation of Clinical Immunology Societies (FOCiS) Annual Meeting
Phenotyping of Human UC Colonic Tissue Reveals Inflammatory Pathway Gene Expression in PD-1+ Conventional and Regulatory T Cells Which Overlap with Those Regulated by Rosnilimab in a Mouse Model of Colitis
Linggi et al., 2025
- Oral Presentation
May, 2025 — Digestive Disease Week (DDW) Annual Meeting
Rosnilimab, a Depleter and Agonist Antibody Targeting PD-1+ T Cells, in Clinical Development for Ulcerative Colitis, Reduces Pathogenic PD-1+ T Cells and Inflammatory Cytokine Secretion in Patient Blood and in a Mouse Model of Colitis
Soroosh et al., 2025
- Poster Presentation
May, 2025 — Digestive Disease Week (DDW) Annual Meeting
Phenotyping of Human UC Colonic Tissue Reveals Inflammatory Pathway Gene Expression in PD-1+ Conventional and Regulatory T Cells Which Overlap with Those Regulated by Rosnilimab in a Mouse Model of Colitis
Linggi et al., 2025
- Poster Presentation
February, 2025 — European Crohn's and Colitis Organisation (ECCO) 2025 Congress
Phenotyping of Human UC Colonic Tissue Reveals Inflammatory Pathway Gene Expression in PD-1+ Conventional and Regulatory T Cells Which Overlap With Those Regulated by Rosnilimab in a Mouse Model of Colitis
Linggi et al., 2025
- Poster Presentation
November, 2024 — American College of Rheumatology (ACR) Convergence 2024
Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Ren et al., 2024
- Poster Presentation
October, 2024 — United European Gastroenterology Week (UEGW)
Rosnilimab, a PD-1 Agonist Antibody in Clinical Development for Ulcerative Colitis, Reduces Pathogenic PD-1+ T Cells and Inflammatory Cytokine Secretion in Patient Blood and in a Mouse Model of Colitis
Parmley et al., 2024
- Oral Presentation
June, 2024 — Federation of Clinical Immunology Societies (FOCiS) Annual Meeting
Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling
Parmley et al., 2024
- Poster Presentation
June, 2024 — Federation of Clinical Immunology Societies (FOCiS) Annual Meeting
Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling
Parmley et al., 2024
- Oral Presentation
May, 2024 — Digestive Disease Week (DDW) Annual Meeting
Optimizing PD-1 Agonist Signaling With Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Parmley et al., 2024
- Poster Presentation
May, 2024 — Digestive Disease Week (DDW) Annual Meeting
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1+ Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial
Luu et al., 2024
- Oral Presentation
February, 2024 — European Crohn’s and Colitis Organisation (ECCO) Congress
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduces T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1high Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial
Luu et al., 2024
- Poster Presentation
February, 2024 — European Crohn’s and Colitis Organisation (ECCO) Congress
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Parmley et al., 2024
- Poster Presentation
November, 2023 — American College of Rheumatology (ACR) Convergence
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial
Luu et al., 2023
- Poster Presentation
June, 2023 — Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
Discovery of a Novel High Affinity Anti-Human CD122 Antagonist Monoclonal Antibody (ANB033) that Abrogates IL-2 and IL-15 Signaling for the Treatment of T Cell-Mediated Inflammatory and Autoimmune Diseases
Hare et al., 2023
- Oral Presentation
September, 2024 — European Academy of Dermatology & Venereology (EADV) Congress
Imsidolimab, an IL-36 Receptor Antagonist, was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients with Generalized Pustular Psoriasis: Results from the Phase 3 Trials, GEMINI-1 and GEMINI-2
Reich et al., 2024
- Poster Presentation
September, 2024 — European Academy of Dermatology & Venereology (EADV) Congress
Imsidolimab, an IL-36 Receptor Antagonist, Was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients With Generalized Pustular Psoriasis Results From the Phase 3 Trials, GEMINI-1 and GEMINI-2
Reich et al., 2024
- Oral Presentation
October, 2021 — European Academy of Dermatology & Venereology (EADV) Annual Congress
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial
Gudjonsson et al., 2021
- Poster Presentation
May, 2018 — European Academy of Allergy and Clinical Immunology (EAACI) Congress
A Phase 1 Study of ANB019, an Anti-Interleukin-36-Receptor (IL-36R) Monoclonal Antibody, in Healthy Volunteers
Khanskaya et al., 2018
- Journal Publication
April, 2023 — British Journal of Dermatology
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial
Warren et al., 2023
- Journal Publication
November, 2013 — Journal of Investigative Dermatology
The Majority of Generalized Pustular Psoriasis Without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist
Sugiura et al., 2013
- Journal Publication
August, 2012 — Current Opinion in Pharmacology
IL-36 in Psoriasis
Towne et al., 2012
- Journal Publication
2012 — Expert Review of Dermatology
IL-36: a Potential Psoriasis Target?
Raison et al., 2012
- Journal Publication
September, 2011 — The American Journal of Human Genetics
Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis
Onoufriadis et al., 2011
- Journal Publication
August, 2011 — The New England Journal of Medicine
Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis
Marrakchi et al., 2011
- Journal Publication
February, 2011 — The Journal of Immunology
IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression
Johnston et al., 2011
- Journal Publication
October, 2007 — Journal of Experimental Medicine
Opposing Activities of Two Novel Members of the IL-1 Ligand Family Regulate Skin Inflammation
Blumberg et al., 2007
- Poster Presentation
2016 — EORTC-NCI-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics
Identification and Characterization of TSR-042, a Novel Anti-PD-1 Therapeutic Antibody
Laken et al., 2016
- Poster Presentation
2016 — EORTC-NCI-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics
Discovery of TSR-022, a Novel, Potent Anti-TIM-3 Therapeutic Antibody
Laken et al., 2016
- Poster Presentation
2015 — American Association for Cancer Research Annual Meeting
Targeting PD-1, TIM-3 and LAG-3 in Combination for Improved Immunotherapy Combinations
Kehry et al., 2015
- Poster Presentation
2015 — Keystone Symposium on Antibodies as Drugs
Generation of Anti-LAG-3 Monoclonal Antibodies for use in Immunotherapy Combinations
Jun et al., 2015
- Poster Presentation
2014 — American Association for Cancer Research Special Conference on Tumor Immunology and Immunotherapy
Identification and Characterization of a Potent Anti-Human Tim-3 Antagonist
Correia et al., 2014
- Poster Presentation
2014 — American Association for Cancer Research Annual Meeting
Generation of Antagonistic Anti-TIM-3 and LAG-3 Monoclonal Antibodies for Potential Novel Immunotherapy Combinations
Jun et al., 2014
- Journal Publication
July, 2021 — mAbs
Preclinical Characterization of Dostarlimab, a Therapeutic Anti-PD-1 Antibody with Potent Activity to Enhance Immune Function in in Vitro Cellular Assays and in Vivo Animal Models
Kumar et al., 2021